Is Streptococcus pyogenes resistant or susceptible to trimethoprim- sulfamethoxazole?

Journal of Clinical Microbiology

Volumn 50, Issue 12, 2012, Pages 4067-4072

  Bowen, Asha C ^a,b   Lilliebridge, Rachael A ^a   Tong, Steven Y C ^a,b   Baird, Robert W ^b   Ward, Peter ^d   McDonald, Malcolm I ^c   Currie, Bart J ^a,b   Carapetis, Jonathan R ^a,e  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c JAMES COOK UNIVERSITY   (Australia)

^d AUSTIN HEALTH   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATHINE PENICILLIN; COTRIMOXAZOLE;

ADOLESCENT; AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; EPSILOMETER TEST; HUMAN; HUMAN TISSUE; IMPETIGO; IN VITRO STUDY; INFANT; MINIMUM INHIBITORY CONCENTRATION; MUELLER HINTON AGAR MEDIUM; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STREPTOCOCCUS PYOGENES;

ADOLESCENT; ANIMALS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CULTURE MEDIA; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EQUIDAE; OVIS ARIES; STREPTOCOCCUS PYOGENES;

EID: 84869236202     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02195-12     Document Type: Article

References (58)

1. Anand C, Gordon R, Shaw H, Fonseca K, Olsen M. 2000. Pig and goat blood as substitutes for sheep blood in blood-supplemented agar media. J. Clin. Microbiol. 38:591-594. (Pubitemid 30082647)
2. Bergner-Rabinowitz S, Davies AM. 1970. Sensitivity of Streptococcus pyogenes types to tetracycline and other antibiotics. Isr. J. Med. Sci. 6:393-398.
3. Bernstein LS. 1982. Combination of trimethoprim with sulfonamides other than sulfamethoxazole. Rev. Infect. Dis. 4:411-418.
4. Brook I, Frazier EH, Yeager JK. 1997. Microbiology of nonbullous impetigo. Pediatr. Dermatol. 14:192-195. (Pubitemid 27255862)
5. Brumfitt W, Hamilton-Miller JMT, Kosmidis J. 1973. Trimethoprim- sulfamethoxazole: the present position. J. Infect. Dis. 128:S778-S791.
6. Bushby SR. 1973. Sensitivity testing with trimethoprim-sulphamethoxazole. Med. J. Aust. 1(Suppl):10-18.
7. Bushby SR. 1973. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J. Infect. Dis. 128(Suppl):442-462.
8. CLSI. 2011. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement M100-S21, p 1-172. Clinical and Laboratory Standards Institute, Wayne, PA.
9. CLSI. 2006. Protocols for evaluating dehydrated Mueller-Hinton agar: approved standard - 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Coburn AF. 1944. The prevention of respiratory tract bacterial infections by sulfadiazine prophylaxis in the United States navy. JAMA 126:88-93.
11. Coll PF, Ausina VR, Vernis JV, Mirelis BO, Prats GP. 1984. Exogenous thymidine and reversal of the inhibitory effect of sulfamethoxazoletrimethoprim on streptococci. Eur. J. Clin. Microbiol. 3:424-426. (Pubitemid 15203254)
12. Dajani AS, Ferrieri P, Wannamaker LW. 1972. Natural history of impetigo. II. Etiologic agents and bacterial interactions. J. Clin. Invest. 51:2863-2871.
13. Damrosch D. 1946. Chemoprophylaxis and sulfonamide resistant Streptococci. JAMA 130:124-128.
14. Darrell JH, Garrod LP, Waterworth PM. 1968. Trimethoprim: laboratory and clinical studies. J. Clin. Pathol. 21:202-209.
15. Delameter ED, Jennings R, Wallace AW. 1946. Preliminary report of an outbreak of Streptococcal disease caused by a sulfadiazine resistant group A, type 17 hemolytic Streptococcus. J. Infect. Dis. 78:118-127.
16. Dhanda V, et al. 2011. Invasive group A streptococcus (GAS) from North India during 2007-2010: surveillance and antibacterial susceptibility, abstr 5, p 18. Abstr. XVIII Lancefield Symp., Palermo, Italy.
17. Domagk G. 1935. Ein Beitrag zur Chemotherapie der Bakteriellen Infektionen. Dtsch. Med. Wochenschr. 61:250-253.
18. Dumre SP, et al. 2009. Asymptomatic throat carriage rate and antimicrobial resistance pattern of Streptococcus pyogenes in Nepalese school children. Kathmandu Univ. Med. J. 7:392-396.
19. Eisen DT. 2010. Tetracycline, p 843-894. In Grayson ML, et al (ed), The use of antibacterials, sixth ed, vol 1. ASM Press, Washington, DC.
20. Eliopoulos GM, Wennersten CB. 1997. In vitro activity of trimethoprim alone compared with trimethoprim-sulfamethoxazole and other antimicrobials against bacterial species associated with upper respiratory tract infections. Diagn. Microbiol. Infect. Dis. 29:33-38. (Pubitemid 27472918)
21. EUCAST. 29 June 2012, posting date. Antimicrobial susceptibility testing. http://www.eucast.org/antimicrobial-susceptibility-testing/disk-diffusion- methodology/.
22. EUCAST. 5 January 2011, posting date. EUCAST MIC and zone diameter breakpoint tables. http://www.eucast.org/antimicrobial-susceptibility-testing/ breakpoints/.
23. Ferone R, Bushby SR, Burchall JJ, Moore WD, Smith D. 1975. Identification of Harper-Cawston factor as thymidine phosphorylase and removal from media of substances interfering with susceptibility testing to sulfonamides and diaminopyrimidines. Antimicrob. Agents Chemother. 7:91-98.
24. Finland M, Garner C, Wilcox C, Sabath LD. 1976. Susceptibility of beta-hemolytic streptococci to 65 antibacterial agents. Antimicrob. Agents Chemother. 9:11-19.
25. Freis ED. 1944. The treatment of tonsillitis with small doses of sulfonamides. JAMA 126:93-94.
26. Geria AN, Schwartz RA. 2010. Impetigo update: new challenges in the era of methicillin resistance. Cutis 85:65-70.
27. Harper GJ, Cawston WC. 1945. The in-vitro determination of the sulphonamide sensitivity of bacteria. J. Pathol. Bacteriol. 57:59-66.
28. Hartman TL, Hoes JS. 1949. The occurrence of a type five sulfadiazine resistant hemolytic streptococcus. J. Pediatr. 34:331-337.
29. Hartman TL, Weinstein L. 1948. The problem of sulfonamide-resistant hemolytic streptococci. N. Engl. J. Med. 238:560-563.
30. Hitchings GH. 1973. Mechanism of action of trimethoprim-sulfamethoxazole. I. J. Infect. Dis. 128(Suppl):433-436.
31. Holbrook WC. 1944. The Army Air Forces Rheumatic Fever Control Program. JAMA 126:84-87.
32. Hoskins TW, Bernstein LS. 1981. Trimethoprim/sulphadiazine compared with penicillin V in the treatment of streptococcal throat infections. J. Antimicrob. Chemother. 8:495-496. (Pubitemid 12173391)
33. Johnson RD, Hartman TL. 1947. Sulfadiazine resistant streptococcal infections in a civilian community. J. Clin. Invest. 26:325-328.
34. Kahlmeter G, et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148. (Pubitemid 36986868)
35. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. 1999. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr. Infect. Dis. J. 18:1069-1072.
36. Koning S, et al. 2012. Interventions for impetigo. Cochrane Database Syst. Rev. 1:CD003261. doi:10.1002/14651858.CD003261.pub3.
37. Lakshmy A, Malhotra VL, Dutta R. 2011. Antibacterial resistance pattern of Streptococcus pyogenes isolated from clinical samples, abstr 36, p 23. Abstr. XVIII Lancefield Symp., Palermo, Italy.
38. Laurell GL, et al. 1968. Streptococcal and staphylococcal infections. World Health Organization technical report series no. 394. World Health Organization, Geneva, Switzerland.
39. Liebowitz LD, Slabbert M, Huisamen A. 2003. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. J. Clin. Pathol. 56:344-347. (Pubitemid 36566818)
40. Maguire GP, Arthur AD, Boustead PJ, Dwyer B, Currie BJ. 1998. Clinical experience and outcomes of community-acquired and nosocomial methicillin-resistant Staphylococcus aureus in a northern Australian hospital. J. Hosp. Infect. 38:273-281. (Pubitemid 28187948)
41. McDonald M, et al. 2006. Recovering streptococci from the throat, a practical alternative to direct plating in remote tropical communities. J. Clin. Microbiol. 44:547-552. (Pubitemid 43222250)
42. McDonald MI, et al. 2006. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian Aboriginal communities where acute rheumatic fever is hyperendemic. Clin. Infect. Dis. 43:683-689. (Pubitemid 44330728)
43. Najjar A, Murray BE. 1987. Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci. Antimicrob. Agents Chemother. 31:808-810. (Pubitemid 17070745)
44. Okafor OO, Akinbami FO, Orimadegun AE, Okafor CM, Ogunbiyi AO. 2011. Prevalence of dermatological lesions in hospitalized children at the University College Hospital, Ibadan, Nigeria. Niger. J. Clin. Pract. 14:287-292.
45. Roberg N. 1946. An epidemic caused by a sulfadiazine resistant strain of the streptococcus hemolyticus (group A, type 17). J. Infect. Dis. 78:135-146.
46. Rubin RH, Swartz MN. 1980. Trimethoprim-sulfamethoxazole. N. Engl. J. Med. 303:426-432. (Pubitemid 10043639)
47. Schultz I, Frank PF. 1958. The prophylactic use of sulfamethoxypyridazine (kynex) during a streptococcal epidemic. Am. J. Med. Sci. 236:779-785.
48. Steer AC, et al. 2009. High burden of impetigo and scabies in a tropical country. PLoS Negl. Trop. Dis. 3:e467. doi:10.1371/journal. pntd.0000467.
49. Stokes A, Lacey RW. 1978. Effect of thymidine on activity of trimethoprim and sulphamethoxazole. J. Clin. Pathol. 31:165-171. (Pubitemid 8280336)
50. Swedberg G, Ringertz S, Skold O. 1998. Sulfonamide resistance in Streptococcus pyogenes is associated with differences in the amino acid sequence of its chromosomal dihydropteroate synthase. Antimicrob. Agents Chemother. 42:1062-1067. (Pubitemid 28227897)
51. Tong SY, et al. 2010. Trimethopim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: a pilot randomised controlled trial. J. Paediatr. Child Health 46:131-133.
52. Tong SY, et al. 2009. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in Indigenous Northern Australia: epidemiology and outcomes. J. Infect. Dis. 199:1461-1470.
53. Tong SY, McDonald MI, Holt DC, Currie BJ. 2008. Global implications of the emergence of community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations. Clin. Infect. Dis. 46:1871-1878.
54. Traub WH, Leonhard B. 1997. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic Streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43:10-20. (Pubitemid 27007922)
55. Trickett PCD, Mogabgab PW. 1973. Trimethoprim-sulfamethoxazole versus penicillinGin the treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis. J. Infect. Dis. 128:S693-S695.
56. Wilson AT. 1945. Method for testing in vitro resistance of group A hemolytic streptococci to sulfonamides. Proc. Soc. Exp. Biol. Med. 58:130-133.
57. Wilson AT. 1954. A simplified method for testing sulfonamide resistance of group A streptococci. J. Lab. Clin. Med. 43:280-285.
58. Yourassowsky E, Vanderlinden MP, Schoutens E. 1974. Sensitivity of Streptococcus pyogenes to sulphamethoxazole, trimethoprim, and cotrimoxazole. J. Clin. Pathol. 27:897-901.